This trial is no longer available!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
CMV Viremia or CMV Disease
and you are
The phase for this study is not defined.
Show me locations

The purpose

This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment options.

Provided treatments

  • Biological: Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03010332. The sponsor of the trial is Atara Biotherapeutics and it is looking for 0 volunteers for the current phase.
Official trial title:
An Expanded Access Protocol of ATA230 (Third-Party Donor-Derived Cytomegalovirus-Specific T Cells) for the Treatment of CMV Viremia or Disease in Subjects for Whom There Are No Other Comparable Options